» Articles » PMID: 37022162

Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the Determination of the Antimicrobial Potency of Compounds

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

The analysis of antimicrobial activity is usually MIC- and minimal bactericidal concentration (MBC)-focused, though also crucial are resistance-related parameters, e.g., the frequency of spontaneous mutant selection (FSMS), the mutant prevention concentration (MPC), and the mutant selection window (MSW). -determined MPCs, however, are sometimes variable, poorly repeatable, and not always reproducible . We propose a new approach to the determination of MSWs, along with novel parameters: MPC-D, MSW-D (for dominant mutants, i.e., selected with a high frequency, without a fitness loss), and MPC-F, MSW-F (for inferior mutants, i.e., with an impaired fitness). We also propose a new method for preparing the high-density inoculum (>10 CFU/mL). In this study, the MPC and MPC-D (limited by FSMS of <10) of ciprofloxacin, linezolid, and novel benzosiloxaborole (No37) were determined for Staphylococcus aureus ATCC 29213 using the standard agar method, while the MPC-D and MPC-F were determined by the novel broth method. Regardless of the method, MSWs of linezolid and No37 were the same. However, MSWs of ciprofloxacin in the broth method was narrower than in the agar method. In the broth method, the 24-h incubation of ~10 CFU in a drug-containing broth differentiates the mutants that can dominate the cell population from those that can only be selected under exposure. We consider MPC-Ds in the agar method to be less variable and more repeatable than MPCs. Meanwhile, the broth method may decrease discrepancies between and MSWs. The proposed approaches may help establish MPC-D-related resistance-restricting therapies.

Citing Articles

Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.

Sussmuth R, Sussmuth R, Kulike-Koczula M, Kulike-Koczula M, Gao P, Kosol S Angew Chem Int Ed Engl. 2024; 64(10):e202414325.

PMID: 39611429 PMC: 11878372. DOI: 10.1002/anie.202414325.


Comparison of the Minimum Inhibitory and Mutant Prevention Drug Concentrations for Pradofloxacin and 7 Other Antimicrobial Agents Tested Against Swine Isolates of and .

Blondeau J, Fitch S Molecules. 2024; 29(22).

PMID: 39598838 PMC: 11597606. DOI: 10.3390/molecules29225448.


Comparison of Resistance Acquisition and Mechanisms in Erwinia amylovora against Agrochemicals Used for Fire Blight Control.

Ham H, Oh G, Lee Y, Lee Y Plant Pathol J. 2024; 40(5):525-536.

PMID: 39397306 PMC: 11471933. DOI: 10.5423/PPJ.OA.07.2024.0106.


In Vitro Resistance-Predicting Studies and In Vitro Resistance-Related Parameters-A Hit-to-Lead Perspective.

Krajewska J, Tyski S, Laudy A Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204172 PMC: 11357384. DOI: 10.3390/ph17081068.


Ethynyl-substituted benzosiloxaboroles: the role of C(π)⋯B interactions in their crystal packing and use in Cu(i)-catalyzed 1,3-dipolar cycloaddition.

Pacholak P, Durka K, Wozniak K, Krajewska J, Laudy A, Lulinski S RSC Adv. 2024; 14(23):16069-16082.

PMID: 38765480 PMC: 11099988. DOI: 10.1039/d4ra02137a.


References
1.
Lopez Y, Tato M, Gargallo-Viola D, Canton R, Vila J, Zsolt I . Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis. PLoS One. 2019; 14(10):e0223326. PMC: 6785070. DOI: 10.1371/journal.pone.0223326. View

2.
Trampari E, Zhang C, Gotts K, Savva G, Bavro V, Webber M . Cefotaxime Exposure Selects Mutations within the CA-Domain of Which Promote Antibiotic Resistance but Repress Biofilm Formation in Salmonella. Microbiol Spectr. 2022; 10(3):e0214521. PMC: 9241649. DOI: 10.1128/spectrum.02145-21. View

3.
Ferran A, Kesteman A, Toutain P, Bousquet-Melou A . Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model. Antimicrob Agents Chemother. 2009; 53(8):3384-90. PMC: 2715583. DOI: 10.1128/AAC.01347-08. View

4.
Liang B, Bai N, Cai Y, Wang R, Drlica K, Zhao X . Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus. Antimicrob Agents Chemother. 2011; 55(5):2409-12. PMC: 3088181. DOI: 10.1128/AAC.00975-10. View

5.
Zhao X, Drlica K . Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis. 2002; 185(4):561-5. DOI: 10.1086/338571. View